Standard BioTools Inc.
NASDAQ Global SelectTotal Valuation
Standard BioTools Inc. carries a market capitalization of 445.02M, placing it among publicly traded companies globally. Its enterprise value stands at -72.59M, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.
| Market Cap | 445.02M |
| Enterprise Value | -72.59M |
Share Statistics
Standard BioTools Inc. currently has 390.14M shares outstanding.
| Shares Outstanding | 390.14M |
| Owned by Insiders (%) | N/A |
| Owned by Institutions (%) | N/A |
Valuation Ratios
Standard BioTools Inc. trades at a trailing price-to-earnings ratio of 4.52. The price-to-sales ratio is 4.09, and the price-to-book ratio stands at -0.31.
| PE Ratio | 4.52 |
| PS Ratio | 4.09 |
| PB Ratio | -0.31 |
| P/TBV Ratio | 0.63 |
| P/FCF Ratio | -4.07 |
| P/OCF Ratio | -3.89 |
Enterprise Valuation
| EV / Sales | 9.23 |
| EV / EBITDA | N/A |
| EV / EBIT | N/A |
| EV / FCF | N/A |
Financial Position
Standard BioTools Inc. maintains a current ratio of 12.36, meaning it holds 12.4x the short-term assets needed to cover near-term liabilities. The debt-to-equity ratio is 5.26, indicating elevated leverage, while an interest coverage ratio of -2,928.83 demonstrates limited ability to service its debt obligations.
| Current Ratio | 12.36 |
| Quick Ratio | 11.77 |
| Debt / Equity | 5.26 |
| Debt / EBITDA | -0.42 |
| Interest Coverage | -2,928.83 |
Financial Efficiency
| Return on Equity (ROE) | N/A |
| Return on Assets (ROA) | 12.83 |
| Return on Invested Capital (ROIC) | N/A |
| Return on Capital Employed (ROCE) | N/A |
| Revenue Per Employee | N/A |
| Employee Count | N/A |
| Inventory Turnover | 1.43 |
Taxes
| Income Tax | -37.75M |
| Effective Tax Rate | N/A |
Stock Price Statistics
Standard BioTools Inc.'s stock has gained approximately 5.55556% over the past 52 weeks. The 50-day moving average sits at 0.97, while the 200-day moving average is 1.22.
| Beta (5Y) | N/A |
| 52-Week Price Change | 5.55556% |
| 50-Day Moving Average | 0.97 |
| 200-Day Moving Average | 1.22 |
| Average Volume (20 Days) | N/A |
Income Statement
Over the trailing twelve months, Standard BioTools Inc. generated 86.26M in revenue and converted that into 78.21M in net income, yielding earnings per share of -0.13. EBITDA reached -70.29M, while operating income came in at -78.51M.
| Revenue | 86.26M |
| Gross Profit | 42.80M |
| Operating Income | -78.51M |
| Pretax Income | -87.83M |
| Net Income | 78.21M |
| EBITDA | -70.29M |
| EBIT | -78.51M |
| Earnings Per Share (EPS) | -0.13 |
Balance Sheet
Standard BioTools Inc. holds 455.18M in cash and equivalents against 29.49M in total debt, resulting in a net debt position of -265.47M. Total book value stands at -1.13B, with working capital of 479.25M providing operational flexibility.
| Cash & Cash Equivalents | 455.18M |
| Total Debt | 29.49M |
| Net Debt | -265.47M |
| Equity (Book Value) | -1.13B |
| Book Value Per Share | -2.95 |
| Working Capital | 479.25M |
Cash Flow
Standard BioTools Inc. produced -90.66M in operating cash flow over the past twelve months. After subtracting -3.82M in capital expenditures, free cash flow totaled -94.48M - equivalent to -0.25 per share.
| Operating Cash Flow | -90.66M |
| Capital Expenditures | -3.82M |
| Free Cash Flow | -94.48M |
| FCF Per Share | -0.25 |
Margins
Standard BioTools Inc. operates with a gross margin of 49.62, reflecting its pricing power and cost economics. The operating margin of -91.02 and net profit margin of 90.67 provide insight into operational efficiency.
| Gross Margin | 49.62 |
| Operating Margin | -91.02 |
| Pretax Margin | -101.82 |
| Profit Margin | 90.67 |
| EBITDA Margin | -81.49 |
Dividends & Yields
| Dividend Per Share | N/A |
| Dividend Yield | N/A |
| Payout Ratio | N/A |
| Shareholder Yield | -0.16 |
| FCF Yield | -24.59 |
Scores
Standard BioTools Inc. posts an Altman Z-Score of 0.86, below the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.
| Altman Z-Score | 0.86 |